Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash from Operations (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Cash from Operations for 3 consecutive years, with 1911000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash from Operations fell 34.77% year-over-year to 1911000.0, compared with a TTM value of 8412000.0 through Dec 2024, up 18.29%, and an annual FY2024 reading of 8412000.0, up 18.29% over the prior year.
  • Cash from Operations was 1911000.0 for Q4 2024 at Oramed Pharmaceuticals, up from 7101000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2076000.0 in Q2 2024 and bottomed at 9125000.0 in Q1 2022.
  • Average Cash from Operations over 3 years is 3885416.67, with a median of 2437500.0 recorded in 2022.
  • Peak annual rise in Cash from Operations hit 178.82% in 2024, while the deepest fall reached 923.2% in 2024.
  • Year by year, Cash from Operations stood at 8062000.0 in 2022, then surged by 82.41% to 1418000.0 in 2023, then crashed by 34.77% to 1911000.0 in 2024.
  • Business Quant data shows Cash from Operations for ORMP at 1911000.0 in Q4 2024, 7101000.0 in Q3 2024, and 2076000.0 in Q2 2024.